本帖最后由 老马 于 2012-1-13 21:20 编辑 7 R, ?9 E7 D8 c
& S" h% G1 t# ?; O Y% k' s/ q2 n爱必妥和阿瓦斯丁的比较
1 [1 }5 i3 V) d! Z1 _
: J' k" _; J% D8 D; R+ ?http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
h1 h# X7 x7 F# e4 P! \ [. D8 }4 s! f
0 A" U7 k2 t' `3 w! e9 r& ?6 Y
3 G3 ]& D- h) Ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
8 ?0 ] k# X/ P, }) K1 h/ t; s7 P==================================================
9 i8 X: m0 x7 E3 f) {+ V7 oOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* o: z0 q# D$ LPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 d( U% h B# A5 i) w+ c7 B, wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ o' S- Q) q9 U) q
|
显身卡
